Combination of Pirfenidone and Andrographolide Ameliorates Hepatic Stellate Cell Activation and Liver Fibrosis by Mediating TGF‐ β /Smad Signaling Pathway
Analytical Cellular Pathology · 2024
DOI: 10.1155/2024/2751280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Cellular Pathology, 2024. Verfasst von Guang Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatal Surgery Hunan Children's Hospital, Changsha 410007, China. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Liver Cirrhosis, Signal Transduction, Diterpenes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Biliary atresia (BA) is a devastating congenital disease characterized by inflammation and progressive liver fibrosis. Activation of hepatic stellate cells (HSCs) plays a central role in the pathogenesis of hepatic fibrosis. Our study aimed to investigate the pharmacological effect and potential mechanism of pirfenidone (PFD) and andrographolide (AGP) separately and together on liver fibrosis of BA. Materials and Methods . The bile ducts of male C57BL/6J mice were ligated or had the sham operation. The in vivo effects of PFD and/or AGP on liver fibrosis of BA were evaluated. Human hepatic stellate cells (LX‐2) were also treated with PFD and/or AGP in vitro .
Results
PFD and/or AGP ameliorates liver fibrosis and inflammation in the mice model of BA, as evidenced by significant downregulated in the accumulation of collagen fibers, hepatic fibrosis markers ( α ‐SMA, collagen I, and collagen IV), and inflammatory markers (IL‐1 β , IL‐6, and TNF‐ α ). Moreover, compared with monotherapy, these changes are more obvious in the combined treatment of PFD and AGP. Consistent with animal experiments, hepatic fibrosis markers ( α ‐SMA, collagen I, and CTGF) and inflammatory markers (IL‐1 β , IL‐6, and TNF‐ α ) were significantly decreased in activated LX‐2 cells after PFD and/or AGP treatment. In addition, PFD and/or AGP inhibited the activation of HSCs by blocking the TGF‐ β /Smad signaling pathway, and the combined treatment of PFD and AGP synergistically inhibited the phosphorylation of Smad2 and Smad3.
Conclusion
The combined application of PFD and AGP exerted superior inhibitive effects on HSC activation and liver fibrosis by mediating the TGF‐ β /Smad signaling pathway as compared to monotherapy. Therefore, the combination of PFD and AGP may be a promising treatment strategy for liver fibrosis in BA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neonatal Surgery Hunan Children's Hospital, Changsha 410007, China.
ORCID-Profile: Guang Xu, Chonggao Zhou, Bixiang Li
Zitieren
APA
Xu, G., Ma, T., Zhou, C., Zhao, F., Peng, K., & Li, B. (2024). Combination of Pirfenidone and Andrographolide Ameliorates Hepatic Stellate Cell Activation and Liver Fibrosis by Mediating TGF‐ β /Smad Signaling Pathway. Analytical Cellular Pathology. https://doi.org/10.1155/2024/2751280
Vancouver
Xu G, Ma T, Zhou C, Zhao F, Peng K, Li B. Combination of Pirfenidone and Andrographolide Ameliorates Hepatic Stellate Cell Activation and Liver Fibrosis by Mediating TGF‐ β /Smad Signaling Pathway. Analytical Cellular Pathology. 2024. doi:10.1155/2024/2751280
BibTeX
@article{Xu2024,
author = {Xu, Guang and Ma, Tidong and Zhou, Chonggao and Zhao, Fan and Peng, Kun and Li, Bixiang},
title = {Combination of Pirfenidone and Andrographolide Ameliorates Hepatic Stellate Cell Activation and Liver Fibrosis by Mediating TGF‐ β /Smad Signaling Pathway},
journal = {Analytical Cellular Pathology},
year = {2024},
doi = {10.1155/2024/2751280}
}
EUVIMED